Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ABCC9 | O60706 | 3/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17877831 | 0.93 | ABCC9 (0.33) | PTGER4ABCC9KDM1A | |
| SCHEMBL17877830 | 0.91 | CYP11B2 (0.41) | FLT3CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL17876216 | 0.90 | MAPK14 (0.32) | ROCK2MAPK14 | |
| SCHEMBL17877896 | 0.88 | EDNRA (0.33) | PTGER4ABCC9KDM1A | |
| SCHEMBL17877829 | 0.88 | ABCC9 (0.36) | PTGER4ABCC9KDM1A | |
| SCHEMBL17877838 | 0.88 | ABCC9 (0.36) | PTGER4ABCC9KDM1A | |
| SCHEMBL17877703 | 0.88 | ABCC9 (0.36) | PTGER4ABCC9KDM1A | |
| SCHEMBL17877834 | 0.88 | ABCC9 (0.36) | PTGER4ABCC9KDM1A | |
| SCHEMBL17876114 | 0.87 | EDNRA (0.39) | FLT3ROCK2ROCK1CYP19A1CYP11B1 | |
| SCHEMBL17877833 | 0.87 | MYC (0.38) | FLT3PTGER4ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10581000-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-03-03 | — | — | US | disclosed |
| US-20160190482-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160190482-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10581000-B2 | Condensed cyclic compound and organic light-emitting device including the same | CRY1, CRY2, CCNE2 | FLT3 2778/4885ROCK2 4451/4885ROCK1 3357/4885 |
| US-20160190482-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNE2 | FLT3 2778/4885ROCK2 4451/4885ROCK1 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.